This review details the characteristic features of three new progestogens which soon will be
available in low-combination oral contraceptive agents in the United States. Available data …

We evaluated the clinical and metabolic effects of a new triphasic regimen developed in the
continuing attempt to reduce the dose of estrogen and progestogen in oral contraceptives. A …

Objective To evaluate the pharmacokinetics of a combined oral contraceptive (OC)
containing oestradiol valerate/dienogest (E2V/DNG) administered according to a four-phasic …

Results from two clinical pharmacokinetic studies are given. The first study was an
observational study in oral contraceptive users who took either a combination of gestodene …

The serum concentrations of ethinylestradiol (EE) during the first 4 h and 24 h after intake of
an oral contraceptive containing 30 μg EE and 75 μg gestodene (EE GSD) were compared …

The efficacy of low-dose oral contraceptives containing 30 µg or 35 µg ethinyl estradiol in
combination with Levonorgestrel, gestoden (Δ15-Levonorgestrel) and cyproterone acetate …

The effect of a triphasic oral contraceptive containing ethinylestradiol and gestodene
(EE/GSD) on various serum hormonal parameters was compared with that of a monophasic …

A multicenter trial was conducted in 267 centers in Italy to evaluate the efficacy, acceptability
and safety of a monophasic oral contraceptive containing 30 micrograms ethinyl estradiol …

The aim of this open-label, multicenter, noncomparative study was to determine the efficacy,
safety and bleeding profile of a new low-dose, monophasic combined oral contraceptive …

Most combination oral contraceptives contain ethinyl estradiol and a progestin. A new and
novel oral contraceptive formulation combines estradiol valerate (E2V) with dienogest …